AKN-028
Names
Biological Activity
[Description]:
AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor (IC50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation[1].
[Related Catalog]:
[Target]
FLT3:6 nM (IC50)
CLK1:140 nM (IC50)
RPS6KA:220 nM (IC50)
VEGFR2:520 nM (IC50)
FGFR2:1200 nM (IC50)
Caspase 3
[In Vitro]
AKN-028 triggers apoptosis in MV4-11 by activation of caspase 3[1]. AKN-028 (10 μM) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11[1]. Cell Cytotoxicity Assay[1] Cell Line: AML cell line MV4-11. Concentration: 10 μM. Incubation Time: 24 h. Result: Was cytotoxic to primary AML cells, irrespective of FLT3 mutation status and quantitative FLT3 expression.
[In Vivo]
AKN-028 (15 mg/kg, Subcutaneously injection twice daily) exhibits anti-tumor activities for acute myeloid leukemia (AML) models[1]. Animal Model: Mice based AML and MV4-11 cells[1]. Dosage: 15 mg/kg. Administration: Subcutaneously injection twice daily. Result: Inhibited net growth of one of the primary AML samples (UPN26) in vivo and furthermore reduced the tumor mass of MV4-11 cell line.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C17H14N6
[ Molecular Weight ]:
302.33300
[ Exact Mass ]:
302.12800
[ PSA ]:
95.74000
[ LogP ]:
3.34880